欧盟 -
挪威文 -
EMA (European Medicines Agency)
xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
挪威 -
挪威文 -
Statens legemiddelverk
eletriptan alternova 20 mg
alternova - eletriptanhydrobromid - tablett, filmdrasjert - 20 mg
挪威 -
挪威文 -
Statens legemiddelverk
eletriptan alternova 40 mg
alternova - eletriptanhydrobromid - tablett, filmdrasjert - 40 mg
挪威 -
挪威文 -
Statens legemiddelverk
indivina 1 mg / 2.5 mg
orion corporation orion pharma - Østradiolvalerat / medroksyprogesteronacetat - tablett - 1 mg / 2.5 mg
挪威 -
挪威文 -
Statens legemiddelverk
indivina 1 mg / 5 mg
orion corporation orion pharma - Østradiolvalerat / medroksyprogesteronacetat - tablett - 1 mg / 5 mg
挪威 -
挪威文 -
Statens legemiddelverk
indivina 2 mg / 5 mg
orion corporation orion pharma - Østradiolvalerat / medroksyprogesteronacetat - tablett - 2 mg / 5 mg
挪威 -
挪威文 -
Statens legemiddelverk
phenergan 25 mg
opella healthcare france sas - prometazinhydroklorid - tablett, filmdrasjert - 25 mg
挪威 -
挪威文 -
Statens legemiddelverk
relpax 40 mg
upjohn eesv - eletriptanhydrobromid - tablett, filmdrasjert - 40 mg
挪威 -
挪威文 -
Statens legemiddelverk
relpax 20 mg
upjohn eesv - eletriptanhydrobromid - tablett, filmdrasjert - 20 mg
欧盟 -
挪威文 -
EMA (European Medicines Agency)
erleada
janssen-cilag international nv - apalutamide - prostata neoplasmer - endokrin terapi - erleada er angitt:i voksne menn for behandling av metastatisk ikke kastrering motstandsdyktig mot prostatakreft (nmcrpc) som har høy risiko for å utvikle metastatisk sykdom. i voksne menn for behandling av metastatisk hormone-sensitive prostatakreft (mhspc) i kombinasjon med androgen mangel terapi (adt).